Medpace (MEDP) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Medpace (MEDP) has outperformed MaxCyte (MXCT) over the past year, gaining 13.6% versus a loss of 32.9%. Over five years, MEDP leads with a +223.0% price change compared with -90.6% for MXCT. Medpace is the larger company by market cap ($16.63 billion vs $101.7 million), about 163.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MEDP | MXCT |
|---|---|---|
| Share price | $595.98 | $0.9853 |
| Market cap | $16.63B | $101.69M |
| 1-day change | -1.37% | -5.26% |
| YTD return | +7.58% | -32.90% |
| 1-year return | +13.61% | -32.90% |
| 5-year return | +222.99% | -90.57% |
| P/E ratio (TTM) | 35.00 | — |
| Forward P/E | 30.85 | — |
| EPS (TTM) | $17.03 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.53B | — |
| Revenue growth (YoY) | +19.97% | — |
| Net income (latest FY) | $451.12M | — |
| Operating margin | 21.14% | — |
| Net margin | 17.83% | — |
| 52-week high | $677.90 | $1.87 |
| 52-week low | $373.00 | $0.643 |
| Distance from 52-week high | -12.08% | -47.17% |
| Analyst consensus | hold | — |
| Avg. price target upside | -0.69% | — |
| Average volume | 275.31K | 685.34K |
| Shares outstanding | 27.91M | 103.21M |
| Employees | 6,500 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medpace is about 163.6 times larger than MaxCyte by market value ($16.63B vs $101.69M).
- MEDP has outperformed MXCT by 46.5 percentage points over the past year.
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
MEDP vs MXCT FAQ
Which is bigger, Medpace or MaxCyte?
Medpace (MEDP) is larger, with a market capitalization of $16.63B compared with $101.69M for MaxCyte (MXCT).
Which stock has performed better over the past year, MEDP or MXCT?
MEDP returned +13.61% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Medpace and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.